Skip to main content

Table 1 Tolerability and effectiveness of different treatment regimens in 504 malaria-patients in Europe

From: Therapy of uncomplicated falciparum malaria in Europe: MALTHER – a prospective observational multicentre study

  Total AQ + PG* MQ* AR + LU* QUI* AR + MQ* QUI + CL* QUI + TC* QUI + AQPG* Other* Overall test
p-Value
N = 504 N = 253 N = 97 N = 39 N = 33 N = 20 N = 20 N = 16 N = 15 N = 11
Treatment change, N (%)            0.0053a
· no change 451 (89.5) 223 (88.1) 92 (94.9) 37 (94.9) 25 (75.8) 19 (95.0) 17 (85.0) 13 (81.3) 15 (100.0) 10 (90.9)  
· due to progress of severity§ 2 (0.4) 2 (0.8) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)  
· due to AE other than vomiting 10 (2.0) 2 (0.8) 0 (0.0) 1 (2.6) 5 (15.2) 1 (5.0) 1 (5.0) 0 (0.0) 0 (0.0) 0 (0.0)  
· due to vomiting 30 (6.0) 22 (8.7) 5 (5.2) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 3 (18.8) 0 (0.0) 0 (0.0)  
· due to other reasons 11 (2.2) 4 (1.6) 0 (0.0) 1 (2.6) 3 (9.1) 0 (0.0) 2 (10.0) 0 (0.0) 0 (0.0) 1 (9.1)  
Pts. with any AE $ , N (%) 82 (16.3) 34 (13.4) 22 (22.7) 1 (2.6) 12 (36.4) 2 (10.0) 7 (35.0) 2 (12.5) 2 (13.3) 0 (0.0) 0.0009 a
Parasite clearance time 72 72 54 72 48 36 48 48 72 48 <0.0001b
Hour median (min-max) (0-168) (0-168) (2-168) (24-168) (24-96) (12-96) (24-96) (24-108) (24-168) (0-96)
Fever clearance time, 48 48 24 48 24 16 48 72 48 36 <0.0001b
Hour median (min-max) (0-192) (0-192) (0-168) (0-72) (0-144) (0-80) (24-96) (24-96) (0-168) (4-60)
Duration of hospitalization # 4 4 4 4 6 3.5 5 5 3.5 4 0.0002 b
Day median (min-max) (1-18) (2-15) (1-18) (2-7) (1-13) (1-18) (3-7) (3-8) (3-7) (1-7)
Cure rate at day 28 & 372/376 191/194 73/73 97.0 25/25 9/9 11/11 10/10 13/13 8/8 0.7371a
N cured/N followed-up (%) (98.9) (98.5) (100.0) (33) (100.0) (100.0) (100.0) (100.0) (100.0) (100.0)  
  1. a : Monte Carlo estimate for the exact chi-square test (1000000 samples); b : Kruskal-Wallis Test.
  2. Figures in bold italics indicate Bonferroni-Holm adjusted p-values <0.05 in against all other comparison.
  3. * : see additional file 1.
  4. § : according to the WHO 2000 severity criterion.
  5. $ : includes possible, mild adverse events.
  6. # : N = 401 (95 non hospitalized patients and 8 with missing data).
  7. & : complete case analysis (128 patients lost to follow-up not included in cure rate calculation; numbers of patients with follow-up data are given in the denominators of the cure rate).